The findings, presented at the 2020 ASCO Virtual Scientific Program, are the first to show benefit with pembrolizumab in patients with advanced colorectal cancer when used as a front-line therapy.
Thierry André, MD
Advertisement
Articles by Thierry André, MD
Advertisement
Latest Updated Articles
Thierry André, MD, on Interim Results from the Phase III Keynote-177 StudyPublished: June 1st 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
2
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
3
Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy
4
3 Things You Should Know About Single-Agent ADCs in TNBC Treatment
5
